*Sponsored by NanoViricides, Inc
NNVC Just Snagged Major FDA Validation for Measles and Now This Low-Key Biotech Is Starting to Look Like a High-Upside Antiviral Contender Right as Virus Fears Heat Back Up Globally!
A revolutionary broad-spectrum antiviral drug NV-387 has been GRANTED Orphan Drug Designation by the US FDA for Measles treatment (May 2026), and its Phase II Clinical Trial for MPox is now imminent in the DRC A
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Zacks Small-Cap Research (Zacks SCR) recently issued coverage with a $7.00 price target
___________________________
Hello Everyone,
The markets just exploded through all time highs and small caps are starting to catch fire.
Our last one saw an average trade of $8.40 on the session with highs of $9.75 the very next session on Thursday. It definitely made the holiday weekend a little more enjoyable. Before that the gold company that we have been telling you about since the $6 level opened at 15.28 and hit 16.69 the next session. The profile before that has been inching up as well. It was a great week for our profiles if you take a look back.
We are hoping to keep the momentum rolling this week with a few profiles that have unique catalysts driving them right now.
Taking a look at a profile for today’s session that we haven’t looked at since way back in October when it opened at $1.60 and a week later it smashed through resistance and hit the $2.22 52-week high.
Since then a lot has changed with the company and interest has really started to pick up. Ebola is back in the news and people are worried. This company is working on the answer.
NNVC is stepping into a powerful spotlight after landing FDA Orphan Drug Designation for its antiviral NV-387 targeting measles—a move that instantly elevates the story from speculative to strategically significant. With measles cases resurging and no approved antiviral treatments currently available, this designation does more than add credibility—it opens the door to faster development timelines, financial incentives, and potential market exclusivity. In a market that reacts quickly to FDA-driven momentum, this kind of news can be a serious attention magnet. In a market that reacts fast to FDA milestones, NNVC just checked a major box!What makes this even more compelling is that NV-387 isn’t a one-virus play—it’s designed as a broad-spectrum antiviral, potentially tackling RSV, influenza, coronaviruses, Mpox, and more. This isn’t just about one virus—NNVC’s platform is built to take on multiple viral threats with a single approach. That gives NNVC exposure to multiple billion-dollar opportunities with a single platform, all while Phase II trials begin to push the science closer to real-world validation.
NanoViricides, Inc. (NNVC) is pioneering a breakthrough approach to antiviral drug development with its lead candidate NV-387, currently advancing through Phase II clinical trials. This first-in-class compound has demonstrated exceptional efficacy in preclinical models against Influenza, RSV, COVID-19, MPox, and Smallpox—consistently outperforming leading antivirals such as Tamiflu, Remdesivir, and Tecovirimat.
NV-387 introduces a revolutionary “empiric therapy” paradigm that could transform how viral infections are treated. Unlike traditional antivirals, NV-387 allows physicians to begin treatment immediately—without waiting for viral identification. This capability positions NV-387 to capture a multi-billion-dollar global market, estimated at over $20 billion for broad-spectrum respiratory antivirals alone.
In addition, NV-387 is being evaluated for MPox treatment in Africa under preliminary regulatory authorization, with plans to extend these studies to Smallpox under the FDA’s Animal Rule pathway. Success in these areas could establish NNVC as a key global player in pandemic preparedness.
The company is pursuing Orphan Drug Designations and Priority Review Vouchers (PRVs)—which could translate into exclusive market access, accelerated approval timelines, and substantial non-dilutive revenue streams through voucher monetization.
Beyond NV-387, NNVC is advancing NV-HHV-1, targeting Shingles, Chickenpox, and HSV infections, as well as novel anti-HIV therapies that have shown best-in-class efficacy in humanized models.
The company’s proprietary nanoviricide platform mimics the natural virus-binding sites on host cells, enabling it to neutralize viruses before they can infect—a mechanism that bypasses traditional resistance pathways. This platform has the potential to address dozens of viral diseases, from Ebola and Dengue to seasonal influenza, offering broad and scalable commercialization opportunities.
With a fully operational cGMP manufacturing facility, a strong global IP portfolio, and a clear roadmap of value-driving milestones for 2025–2026—including Phase II results, new IND filings, and orphan drug approvals—NanoViricides is poised to deliver transformational growth and long-term shareholder value.
In an era of increasing viral threats, NNVC stands at the forefront of next-generation antiviral innovation—offering investors a rare opportunity to participate in a company with both scientific depth and exponential market potential.
Rising Viral Burden and the Opportunity for NV-387
In 2026, Measles cases have continued their alarming surge: as of April 30, 2026, already 1,803 confirmed cases have been reported in the United States alone — while 2025 saw 2,251 confirmed cases with 3 deaths (up from 285 in 2024 and 59 in 2023). Globally, Bangladesh has reported over 35,000 cases with 227 children dead, and Guatemala over 5,300 cases with 4 deaths. The current severe 2025–2026 Influenza season (subclade K H3N2, responsible for 80%+ of cases) has caused an estimated 15 million illnesses, 180,000 hospitalizations, and 7,400 deaths in the US — with the seasonal vaccine mismatched and substantially less effective. Meanwhile, MPox Clade I continues to spread, with 15 new cases reported in the USA since November 2025, including evidence of community spread in California.
Against this backdrop of spiraling outbreaks and limited therapeutic options, the broad-spectrum drug candidate NV-387 (by NanoViricides, Inc./NNVC) — now advancing through Phase II clinical trials for MPox and targeting RSV, Influenza/Bird Flu, COVID/long COVID, Measles, Mpox/Smallpox and more — presents a timely opportunity to invest in the development of a revolutionary “first visit” anti-viral treatment that is safe, nontoxic and works even as variants emerge.
Top Reasons to Have NNVC on Your Radar
Breakthrough Lead Candidate – NV-387:A revolutionary broad-spectrum antiviral that directly targets and destroys virus particles — showing strong results against Mpox, Measles, RSV, Influenza, and COVID-19 in animal trials.
Proven Safety in Humans:NV-387 successfully completed Phase I human clinical trials with no reported adverse events, demonstrating excellent safety and tolerability.
Advancing Toward Phase II Trials:NV-387’s Phase II Clinical Trial for MPox is now actively commencing in the DRC, with full regulatory approval from ACOREP received and CRO site preparations complete. Patient enrollment and dosing are beginning — a critical step toward demonstrating clinical effectiveness and potential drug approval.
Broad Market Opportunity:With its lead drug NV-387, NanoViricides targets a global antiviral market exceeding $11 Billion across known indications (RSV, Measles, Mpox/Smallpox, COVID/Long COVID and Influenza), and a potential $20 Billion+ market for emperic antiviral therapy of all respiratory viral infections. With NV-387 addressing multiple high-value segments, and other drugs in the pipeline addressing other virus families like Herpes (Shingles) and HIV, NNVC is positioned to capture a substantial share of the rapidly growing global market for antiviral drug treatments.
Dual-Track Clinical Strategy:With its dual-track strategy now fully operational — Phase II MPox trial commencing in DRC (biodefense track) and FDA Orphan Drug Designation secured for Measles (commercial respiratory track) — NanoViricides is accelerating development timelines and expanding revenue potential across both government stockpiling contracts and commercial markets.
Orphan Drug and Regulatory Designations:NV-387 has been GRANTED Orphan Drug Designation by the US FDA for Measles treatment (May 2026) — qualifying for 7 years of market exclusivity, tax credits for clinical trials, and fee exemptions. An Orphan Drug Designation application for MPox has also been filed (February 2026). Additionally, a Rare Pediatric Disease Drug Designation application has been filed for Measles, making NNVC eligible for a tradable Priority Review Voucher worth approximately $160 million upon drug approval.
Manufactured in the USA:NanoViricides fully owns a cGMP-capable facility in Shelton, CT with no mortgage or liens, enabling in-house production for clinical trials, quality & IP control, and cost efficiency.
Strong Intellectual Property and Global Patents:Backed by TheraCour® nanomedicine technology with exclusive, perpetual global licenses across multiple viral diseases.
Debt-Free Balance Sheet:NNVC maintains a debt-free financial position, with no warrants, preferred warrants, or loans, giving it strategic flexibility to pursue development and funding opportunities efficiently.
Annual Report Highlights:The FY2025 Annual Report reflects strong asset management with over $8.5M in R&D and infrastructure investments and continued financial discipline toward Phase II readiness.
Strong Biodefense Alignment:NV-387 aligns with U.S. BARDA and Strategic National Stockpile (SNS) programs. US Government SNS stockpiling contracts for existing smallpox drugs TPOXX and TEMBEXA have been in several hundreds of millions of dollars — representing an equivalent potential opportunity for NV-387. With TPOXX’s clinical trial failing to show efficacy over placebo (August 2024), NV-387 is positioned as a critical next-generation biodefense candidate.
Pipeline Diversity and Expansion:NanoViricides’ multi-drug pipeline includes 10+ antiviral programs, positioning the company to address both existing diseases and future viral threats with speed and scalability.
Expert Orphan Drug Strategy Team:NanoViricides has signed a Master Services Agreement with OnlyOrphansCote, LLC — founded by Dr. Timothy Cote, former Director of the US FDA Office of Orphan Products Development (OOPD). Dr. Cote brings intimate knowledge of orphan drug laws, regulations, and the approval process, significantly strengthening NNVC’s regulatory development pathway for MPox, Smallpox, and Measles indications.
The Growing Gap in Viral Disease Treatment
While bacterial infections are treated on “first visit” with broad spectrum antibiotics, the world still lacks effective, broad-spectrum therapies that can treat viral infections immediately after symptoms appear, without waiting for tests to determine which virus. That is why outbreaks of Mpox, RSV, Influenza, COVID-19, and Measles continue to surge despite rapid advances in vaccines, with millions affected globally each year.
Existing treatments are virus-specific and quickly lose effectiveness as viruses mutate into variants. In many viral infections, especially emerging and re-emerging diseases, no direct therapeutic treatment drugs exist.
The current 2025–2026 Influenza season starkly illustrates this gap: the seasonal vaccine was mismatched against the dominant H3N2 subclade K variant, rendering it substantially less effective. Existing antivirals like Tamiflu (oseltamivir) and Xofluza (baloxavir) must be taken within 48 hours of symptom onset and influenza viruses can rapidly develop resistance to both — leaving millions without effective treatment. A clinical trial of tecovirimat (TPOXX) for MPox failed to demonstrate any effectiveness over placebo (NIH, August 2024), further highlighting that even virus-specific drugs are failing. There is currently no approved drug for Measles treatment despite the global epidemic.
The growing frequency of pandemics and falling vaccination rates highlight a major unmet medical need: a safe, nontoxic broad-spectrum antiviral therapy capable of addressing multiple viral threats simultaneously. NanoViricides’ NV-387 directly targets this global gap with its innovative Bind–Engulf–Destroy mechanism.
NNVC’s dual-track clinical strategy is now fully operational with major regulatory milestones achieved in rapid succession:
Track 1 — MPox/Smallpox (Biodefense): The Phase II Clinical Trial for MPox treatment in the DRC has received full regulatory approval from ACOREP (November 2025) and is now actively commencing — CRO site preparations by Om Sai Clinical Research (India) are complete, staff training underway in April 2026 , with patient enrollment and dosing beginning immediately after. The trial will evaluate safety and effectiveness of NV-387 in patients with MPox Clade I disease. An Orphan Drug Designation application for MPox has been filed with the US FDA (February 2026).
Track 2 — Respiratory Viral Diseases (Commercial): NV-387 targets Measles, RSV, Influenza, and COVID/long COVID. On May 4, 2026, the US FDA GRANTED Orphan Drug Designation [i] for NV-387 as a Treatment for Measles — qualifying for 7 years of market exclusivity, tax credits, and fee waivers. A Rare Pediatric Disease Drug Designation application has also been filed (April 2026), making NNVC eligible for a Priority Review Voucher (PRV) worth approximately $160 million upon drug approval.
NV-387 has already completed a Phase I clinical trial in 2023 with no reported adverse events, demonstrating excellent safety and tolerability in humans.
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to perform a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus has been approved by the Pillar Committee in Charge in the Democratic Republic of Congo (DRC).
There is no approved treatment or vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DR Congo and Uganda. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.
NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same feature mimicked by NV-387.
NV-387 is the only orally active agent under consideration for clinical trial as a treatment of Ebola to the best of our knowledge. In an epidemic scenario in resource limited settings such as in DRC, oral drug is a highly advantageous feature.
Other treatments require infusions. Infusions are difficult to implement and also are not scalable in a large outbreak scenario if this Ebola virus outbreak continues to grow, as has been widely expected.
“We believe NV-387 could be effective against Ebola viruses,” said Anil R. Diwan, PhD, adding, “It is an oral drug, in contrast to other infusions, which makes for easy scalability of NV-387 treatment in this lethal disease theater to treat the most number of patients while requiring the least amount of healthcare resources. Thus evaluating if NV-387 treatment works is of paramount importance to combat this outbreak.”
NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for the Phase II Mpox clinical trial in DRC previously. Om Sai CRO has been instrumental in the successful submission, in a rapid timeframe, of our proposal to the Pillar Committee for the Phase II Clinical Trial for Evaluation of NV-387 Oral Gummies as a Treatment of Ebola Viruses in DRC.
The next steps for NanoViricides will be to perform appropriate submissions to the National Ethics Committee of DRC, and upon their approval, to submit a clinical trial application to the regulatory agency, ACOREP for approval to begin the clinical trial. Most of these documents are ready because the same drug NV-387 Oral Gummies has been approved by ACOREP for a Phase II clinical trial as a Treatment for Mpox in DRC.
The Bundibugyo Ebola Viral Disease (BVD) outbreak has already expanded to 782 confirmed cases, with 181 deaths reported as of June 14 in DR Congo. It has expanded to two additional health zones, covering 20 of the 36 zones, in the Ituru province where it started, with 10 of 34 zones in North Kivu and 1 health zone in South Kivu provinces reporting increasing numbers of cases[2].
While there is currently minimal risk of Ebola in the USA, the CDC’s mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths in the next three months alone, rivaling the largest outbreak to date in 2014-2016[3].
The outbreak which was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk[4].
Infusions with a new antibody cocktail, MBP134 (ZMapp), or a monoclonal antibody, Maftivimab (Regeneron), or a nucleotide analog Remdesivir are being considered for treatment and are likely to advance into clinical trials.
All of these potential treatments require I.V. infusions with most requiring multiple infusions. This is very difficult to implement in the low resource environment, complicated with the lethal disease scenario of extreme isolation suites, and healthcare workers covered with PPE. Further, monoclonal antibodies are highly specific to the strain of virus and usually are not effective against unrelated strains.
Further, viruses readily escape antibodies after exposure to the drugs.
In contrast, NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.
This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.
Additionally, NV-387 was previously found to be superior to remdesivir in a lethal animal model of a viral disease. The Company believes this superiority of NV-387 is very likely to extend to the current novel Bundibugyo ebolavirus strain.
Further, it is highly unlikely that viruses can escape NV-387, because this drug mimics the features on host cells that the viruses continue to require even as they mutate or evolve in the field.
NV-387 Oral Gummies drug product is ready to be shipped to DRC for the impending Phase II clinical trial of NV-387 as a Treatment for Mpox. It will thus be immediately locally available to combat the Ebola outbreak if it shows effectiveness against Ebola Bundibugyo in patients.
These factors presented a compelling case making NV-387 a strong contender for conducting Phase II clinical trials as a treatment of the Bundibugyo Virus (BDBV) infection and the resulting Bundibugyo Virus Disease (BVD).
NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate proteoglycan that over 90-95% of human pathogenic viruses require for infecting cells. No matter how much the virus changes in the field, it continues to use HSPG, and therefore it cannot escape the drug NV-387. In contrast, Remdesivir is a small molecule inhibitor of the viral RDRP enzyme needed for making copies of the viral genome, and the virus can possibly escape by small number of mutations.
All Ebola viruses utilize HSPG as the attachment receptor, followed by entry into the cell inside endosomes. The virus substantially dismantles in the endosome and hitches a cognate receptor called NPC1 to enter the cytoplasm where the next steps in its replication begin.
Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.
NV-387 is available as an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.
If NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses or all filoviruses; that would be a game changer for pandemic preparedness.
NEWS
6 days ago
Jun 8, 2026
May 26, 2026
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
May 18, 2026
May 18, 2026
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
May 15, 2026
NanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase II
May 15, 2026
May 11, 2026
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
May 6, 2026
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
May 4, 2026
MANAGEMENT
Anil R. Diwan, PhD
Executive Chairman, President
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.
Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: 3rd party on behalf of NanoViricides, Inc
Amount of Cash Compensation: fifteen thousand usd
Period of Publication of Information: One day campaign beginning and ending on June twenty second twenty twenty six
Previous Compensation: One or more partners of Dedicated Investors LLC has been previously compensated one hundred eighteen thousand five hundred usd on behalf of NanoViricides, Inc.
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.